title: Neuroprotective Effects of rhGLP-1 in Diabetic Rats with Cerebral Ischemia/Reperfusion Injury.
abstract: Preclinical Research The aim of the present study was to evaluate the neuroprotective benefits of rhGLP-1 in diabetic rats subjected to acute cerebral ischemia/reperfusion injury induced by middle cerebral artery occlusion/reperfusion (MCAO/R). Streptozotocin (STZ)-induced diabetic rats were pretreated with rhGLP-1 (10, 20, or 40 μg/kg ip, tid) for 14 days. During this time, body weight and fasting blood glucose levels were assessed. Rats were then subjected to MCAO 90 min/R 24 h. At 2 and 24 h of reperfusion, rats were evaluated for neurological deficits and blood samples were collected to analyze markers of brain injury. Rats were then sacrificed to assess the infarction volume. rhGLP-1 pretreatment lowered blood glucose levels, improved neurological scores, attenuated infarct volumes, and reduced the blood levels of S100 calcium-binding protein B (S100B), neuron-specific enolase (NSE), and myelin basic protein (MBP). rhGLP-1 has neuroprotective benefits in diabetic rats with cerebral ischemia/reperfusion injury and could potentially be used as a prophylatic neuroprotectant in diabetic patients at high risk of ischemic stroke. Drug Dev Res 77 : 124-133, 2016.   © 2016 Wiley Periodicals, Inc.
authors.affiliation: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical College, Xuzhou, 221004, China.
authors.forename: Daoli
authors.initials: D
authors.lastname: Jiang
authors.affiliation: Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China.|Department of Pharmacy Administration and Clinical Pharmacy, Peking University Health Science Center, Beijing, 100191, China.
authors.forename: Yitong
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China.|Department of Pharmacy Administration and Clinical Pharmacy, Peking University Health Science Center, Beijing, 100191, China.
authors.forename: Yannan
authors.initials: Y
authors.lastname: Zang
authors.affiliation: Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
authors.forename: Xiaofang
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China.
authors.forename: Libo
authors.initials: L
authors.lastname: Zhao
authors.affiliation: Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical College, Xuzhou, 221004, China.
authors.forename: Chang
authors.initials: C
authors.lastname: Liu
authors.affiliation: Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China.
authors.forename: Wanyu
authors.initials: W
authors.lastname: Feng
authors.affiliation: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical College, Xuzhou, 221004, China.
authors.forename: Xiaoxing
authors.initials: X
authors.lastname: Yin
authors.affiliation: Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Fang
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002545:Brain Ischemia / Q000097:blood / Q000188:drug therapy*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D004195:Disease Models, Animal; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage* / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D004676:Myelin Basic Protein / Q000097:blood; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000494:pharmacology; D010751:Phosphopyruvate Hydratase / Q000097:blood; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D015427:Reperfusion Injury / Q000097:blood / Q000188:drug therapy*; D064568:S100 Calcium Binding Protein beta Subunit / Q000097:blood; D013311:Streptozocin; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D004676:Myelin Basic Protein; D018696:Neuroprotective Agents; D011994:Recombinant Proteins; D064568:S100 Calcium Binding Protein beta Subunit; C579160:S100B protein, human; D013311:Streptozocin; D052216:Glucagon-Like Peptide 1; D010751:Phosphopyruvate Hydratase
keywords: cerebral ischemia/reperfusion injury; diabetes; rhGLP-1